Kiniksa Pharmaceuticals International, plc Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost
Kiniksa Pharmaceuticals International, plc (KNSA) had Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost of $13.33 million as of 2025-12-31, per its 10-K filed 2026-02-24.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Components of Deferred Tax Assets › Deferred Tax Assets, Net of Valuation Allowance › Deferred Tax Assets, Gross › Deferred Tax Assets, Tax Deferred Expense
us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost · last filed 2026-02-24
- 2025-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost $13.33M.
- 2024-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost $16.30M.
- 2023-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost $15.64M.
- 2022-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost $11.79M.
| Period end | Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost |
|---|---|
| 2025-12-31 | $13.33M 10-K · filed 2026-02-24 |
| 2024-12-31 | $16.30M 10-K · filed 2026-02-24 |
| 2023-12-31 | $15.64M 10-K · filed 2025-02-25 |
| 2022-12-31 | $11.79M 10-K · filed 2024-02-28 |
| 2021-12-31 | $9.49M 10-K · filed 2023-03-02 |
| 2020-12-31 | $6.27M 10-K · filed 2022-02-24 |
| 2019-12-31 | $3.75M 10-K · filed 2021-02-25 |
| 2018-12-31 | $1.00M 10-K · filed 2020-03-05 |